| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Cyclopharm Ltd
ASX:CYC
Cyclopharm Ltd
Total Equity
Cyclopharm Ltd
Total Equity Peer Comparison
NTI
IPD
COH
OIL
EMV
Competitive Total Equity Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
Total Equity
AU$32.3m
|
CAGR 3-Years
24%
|
CAGR 5-Years
14%
|
CAGR 10-Years
24%
|
|
|
Neurotech International Ltd
ASX:NTI
|
Total Equity
AU$4.8m
|
CAGR 3-Years
36%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
ImpediMed Ltd
ASX:IPD
|
Total Equity
AU$51m
|
CAGR 3-Years
27%
|
CAGR 5-Years
14%
|
CAGR 10-Years
21%
|
|
|
Cochlear Ltd
ASX:COH
|
Total Equity
AU$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
22%
|
CAGR 10-Years
19%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Total Equity
AU$16.4m
|
CAGR 3-Years
17%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Total Equity
AU$5.1m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
See Also
What is Cyclopharm Ltd's Total Equity?
Total Equity
32.3m
AUD
Based on the financial report for Dec 31, 2023, Cyclopharm Ltd's Total Equity amounts to 32.3m AUD.
What is Cyclopharm Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
24%
Over the last year, the Total Equity growth was -12%. The average annual Total Equity growth rates for Cyclopharm Ltd have been 24% over the past three years , 14% over the past five years , and 24% over the past ten years .
You don't have any saved screeners yet
